These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

840 related items for PubMed ID: 27652617

  • 1. Cardiovascular safety of therapies for type 2 diabetes.
    Gupta P, White WB.
    Expert Opin Drug Saf; 2017 Jan; 16(1):13-25. PubMed ID: 27652617
    [Abstract] [Full Text] [Related]

  • 2. Novel antidiabetic drugs and cardiovascular risk: Primum non nocere.
    Bonadonna RC, Borghi C, Consoli A, Volpe M.
    Nutr Metab Cardiovasc Dis; 2016 Sep; 26(9):759-66. PubMed ID: 27373139
    [Abstract] [Full Text] [Related]

  • 3. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
    Schernthaner G, Schernthaner-Reiter MH, Schernthaner GH.
    Clin Ther; 2016 Jun; 38(6):1288-1298. PubMed ID: 27210264
    [Abstract] [Full Text] [Related]

  • 4. Cardiovascular outcomes of sodium-glucose cotransporter 2 inhibitors: A comprehensive review of clinical and preclinical studies.
    Ghosh RK, Bandyopadhyay D, Hajra A, Biswas M, Gupta A.
    Int J Cardiol; 2016 Jun 01; 212():29-36. PubMed ID: 27017118
    [Abstract] [Full Text] [Related]

  • 5. Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors.
    Scheen AJ.
    Circ Res; 2018 May 11; 122(10):1439-1459. PubMed ID: 29748368
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Impact of EMPA-REG OUTCOME® on the management of type 2 diabetes mellitus: a review for primary care physicians.
    Naing S, Poliyedath A, Khandelwal S, Sigala T.
    Postgrad Med; 2016 Nov 11; 128(8):822-827. PubMed ID: 27701934
    [Abstract] [Full Text] [Related]

  • 8. Mitigating Cardiovascular Risk in Type 2 Diabetes With Antidiabetes Drugs: A Review of Principal Cardiovascular Outcome Results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 Trials.
    Kaul S.
    Diabetes Care; 2017 Jul 11; 40(7):821-831. PubMed ID: 28637887
    [Abstract] [Full Text] [Related]

  • 9. Cardiovascular Protection with Anti-hyperglycemic Agents.
    Deedwania P, Acharya T.
    Am J Cardiovasc Drugs; 2019 Jun 11; 19(3):249-257. PubMed ID: 30767126
    [Abstract] [Full Text] [Related]

  • 10. Cardiovascular benefits and safety of non-insulin medications used in the treatment of type 2 diabetes mellitus.
    Yandrapalli S, Jolly G, Horblitt A, Sanaani A, Aronow WS.
    Postgrad Med; 2017 Nov 11; 129(8):811-821. PubMed ID: 28749197
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [Analysis of cardiovascular safety of novel glucose-lowering medications].
    Mkrtumyan AM, Markova TN, Mishchenko NK.
    Kardiologiia; 2019 Jul 19; 59(7):76-83. PubMed ID: 31322093
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. A Multifactorial Approach to Reduce Cardiovascular Disease in Type 2 Diabetes Mellitus: Now More Than Ever.
    Basile JN.
    Hosp Pract (1995); 2016 Jul 19; 44(1):9-20. PubMed ID: 26781810
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. [Cardiovascular protection of patients with type 2 diabetes : from EMPA-REG OUTCOME to LEADER].
    Scheen AJ, Wallemacq C, Jandrain B, Ernest P.
    Rev Med Suisse; 2016 Aug 24; 12(527):1370-1375. PubMed ID: 28671791
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 42.